Ceredex Value Advisors LLC purchased a new position in Perrigo (NYSE:PRGO) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 981,350 shares of the company’s stock, valued at approximately $81,786,000. Perrigo makes up 1.0% of Ceredex Value Advisors LLC’s investment portfolio, making the stock its 28th biggest position. Ceredex Value Advisors LLC owned approximately 0.70% of Perrigo as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Twin Tree Management LP boosted its position in Perrigo by 271.0% during the 1st quarter. Twin Tree Management LP now owns 2,223 shares of the company’s stock worth $185,000 after acquiring an additional 3,523 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Perrigo by 8.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 549,100 shares of the company’s stock worth $45,762,000 after acquiring an additional 42,845 shares during the period. Goodman Financial Corp boosted its position in Perrigo by 4.9% during the 1st quarter. Goodman Financial Corp now owns 63,436 shares of the company’s stock worth $5,287,000 after acquiring an additional 2,971 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in Perrigo by 31.1% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 69,139 shares of the company’s stock worth $5,762,000 after acquiring an additional 16,406 shares during the period. Finally, Prudential Financial Inc. boosted its position in Perrigo by 70.1% during the 1st quarter. Prudential Financial Inc. now owns 303,556 shares of the company’s stock worth $25,298,000 after acquiring an additional 125,150 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.
PRGO opened at $75.86 on Friday. Perrigo has a twelve month low of $75.66 and a twelve month high of $76.20. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.48. The company has a market capitalization of $10.46 billion, a P/E ratio of 15.39, a P/E/G ratio of 1.77 and a beta of 0.77.
Perrigo (NYSE:PRGO) last posted its earnings results on Tuesday, May 8th. The company reported $1.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.12. Perrigo had a return on equity of 11.93% and a net margin of 2.59%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the previous year, the company earned $1.05 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. equities analysts expect that Perrigo will post 5.25 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 19th. Investors of record on Friday, June 1st will be issued a $0.19 dividend. The ex-dividend date of this dividend is Thursday, May 31st. This represents a $0.76 annualized dividend and a yield of 1.00%. Perrigo’s dividend payout ratio (DPR) is currently 15.42%.
PRGO has been the subject of a number of research reports. JPMorgan Chase restated a “neutral” rating and set a $83.00 price objective (up from $82.00) on shares of Perrigo in a research report on Monday, March 5th. Oppenheimer reiterated a “buy” rating and set a $98.00 price target on shares of Perrigo in a report on Tuesday, February 27th. Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the company a “buy” rating in a report on Friday, January 19th. Canaccord Genuity set a $105.00 price target on Perrigo and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Berenberg Bank initiated coverage on Perrigo in a report on Thursday, February 1st. They set a “buy” rating and a $117.00 price target for the company. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $93.06.
In other Perrigo news, CEO Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction on Monday, March 5th. The shares were bought at an average cost of $81.85 per share, with a total value of $613,875.00. Following the transaction, the chief executive officer now directly owns 4,900 shares in the company, valued at approximately $401,065. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey C. Smith purchased 50,000 shares of the company’s stock in a transaction on Thursday, May 17th. The stock was acquired at an average cost of $75.89 per share, for a total transaction of $3,794,500.00. Following the completion of the transaction, the director now owns 528 shares in the company, valued at $40,069.92. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 307,500 shares of company stock valued at $23,210,875. Corporate insiders own 6.90% of the company’s stock.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.